Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content
Watch Dr John Isaac introduce the New Therapeutics in Alzheimer's Disease study, known as 'NTAD'.

NTAD will employ magnetoencephalography (MEG) to identify reliable, sensitive and tractable 'biomarkers' – biological signs – of abnormal brain structure that scientists believe is occurring early in Alzheimer’s disease. The aim is to develop a fit-for-purpose set of these identifiers based around MEG that can be used in studies which test novel interventions aimed at halting the progression of Alzheimer's disease.


Cambridge janssen Cardiff AstraZeneca Oxford wide

Our team